NCT01014793View on ClinicalTrials.gov

Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

CompletedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

December 31, 2008

Conditions
Acromegaly
Interventions
DRUG

cabergoline

cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal

Trial Locations (1)

04039030

Federal University of Sao Paulo, São Paulo

All Listed Sponsors
lead

Federal University of São Paulo

OTHER

NCT01014793 - Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients | Biotech Hunter | Biotech Hunter